The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy Subjects

This study has been completed.

Sponsored by:	Daiichi Sankyo Inc.
Information provided by:	Daiichi Sankyo Inc.
ClinicalTrials.gov Identifier:	NCT00185055

Purpose

To assess the effects of 3 blood pressure drugs, called angiotensin receptor blockers, on the blood pressure control systems in healthy subjects.

Condition	Intervention	Phase
Healthy	Drug: Olmesartan medoxomil Drug: Irbesartan Drug: Valsartan	Phase IV

Drug Information available for: Valsartan Aldosterone Irbesartan Olmesartan Olmesartan medoxomil

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study
Official Title:	The Relative Effects of Single Doses of Olmesartan Medoxomil, Irbesartan and Valsartan at High Dosage Levels on the Renin-Angiotensin-Aldosterone System in Healthy Normal Subjects

Further study details as provided by Daiichi Sankyo Inc.:

Primary Outcome Measures:

To characterize the plasma renin activity (PRA) and urinary aldosterone response patterns to single doses of olmesartan medoxomil, irbesartan, and valsartan compared to placebo in normal volunteers.

Estimated Enrollment:	20
Study Start Date:	November 2004
Estimated Study Completion Date:	February 2005

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

No Contacts or Locations Provided

More Information

Study ID Numbers:	866-448
Study First Received:	September 9, 2005
Last Updated:	September 15, 2005
ClinicalTrials.gov Identifier:	NCT00185055
Health Authority:	United States: Food and Drug Administration

Keywords provided by Daiichi Sankyo Inc.:

olmesartan
valsartan
irbesartan
renin-angiotensin-aldosterone system

Study placed in the following topic categories:

Irbesartan
Olmesartan medoxomil
Healthy
Angiotensin II
Valsartan

Additional relevant MeSH terms:

Angiotensin II Type 1 Receptor Blockers
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses

Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009